Having trouble accessing articles? Reset your cache.

Telaprevir: Phase III data

In the open-label, international ILLUMINATE trial in 540 treatment-naïve patients with HCV genotype 1 infection, a 24-week telaprevir-based regimen (n=162) was non-inferior to a 48-week regimen (n=160) on the primary endpoint of the proportion of patients achieving an SVR 24 weeks

Read the full 416 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers